Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company

Read More

Congratulations to our Fierce 15 winners Rhythm, Fulcrum and Neon

Read More

Third Rock launches Relay Therapeutics with $57M to build the world’s first dedicated drug discovery platform centered on protein motion

Read More

Jounce and celgene to collaborate on next-generation immuno-oncology therapies

Read More

Third Rock Launches Fulcrum Therapeutics to Transform Gene Regulation in Disease

Read More

Decibel Therapeutics Appoints Steven H. Holtzman as President and Chief Executive Officer

Read More

Merck to Acquire Afferent for up to $1.25 billion

Read More

Partner Profile: Kevin Gillis

Read More

Congratulations to Our 2016 NEVY Award Winners Editas Medicine and Decibel Therapeutics

Read More

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology

Read More

CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates

Read More

Nature Biotechnology highlights Neon Therapeutics in it's list of academic spinouts of 2015

Read More

Congratulations to Voyager Therapeutics on being named one of The Boston Business Journal's 2016 Best Places to Work

Read More

Take a look at what we’ve been up to for the past 8+ years

Watch the Video

Sign up for weekly portfolio company news alerts here
 

Read More

Andrew Stricos, who has Huntington’s disease, and his wife tell their story at a luncheon hosted by Third Rock

Watch the Video

Transforming Healthcare

40

Portfolio Companies
With More Than $1.3 Billion
Under Management

45

Clinical Studies
Underway Within Our Portfolio

60

Diseases
Being Targeted By
Our Companies

10  

of thousands

Patients Impacted
By Portfolio Company Products
and Clinical Trials